Table 3.
Median overall survival in AZA-001 trial according to cytogenetic risk
| Cytogenetic risk group | % pts (n/N) |
Median overall survival (months) |
HR (95% CI) | Pvalue log rank | |
|---|---|---|---|---|---|
| AZA | CCR | ||||
| Good (normal, del(5q), del(20q) | 46 (166/358) | Not reached | 17.1 | 0.61 (0.39–0.96) | 0.030 |
| Intermediate (other) | 21 (76/358) | 26.3 | 17.0 | 0.43 (0.21–0.88) | 0.017 |
| Poor (complex, −7) | 28 (100/358) | 17.2 | 6.0 | 0.52 (0.32–0.87) | 0.011 |
Reprinted from Lancet Oncol, 10, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase II study, 223–232,48 Copyright © 2009, with permission from Elsevier.
Abbreviations: AZA, azacitidine; CCR, conventional care regimens; CI, confidence interval; HR, hazard ratio.